共 50 条
- [21] Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 622 - 624
- [22] A quest for stakeholder synchronization in the CAR T-cell therapy supply chain [J]. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2024, 12
- [23] CAR T-Cell Optimization Starts in Production, Extends to Therapy [J]. 1600, Mary Ann Liebert Inc. (40):
- [24] The PO4-tential for Less Toxic CAR T-cell Therapies [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (12) : 1422 - 1422
- [25] Keynote Session: Experience With Innovative Therapies A Focus on CAR T-Cell Therapy [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05): : 548 - 550
- [26] Customer pyramid framework for CAR T-cell therapies in immuno-oncology [J]. DRUG DISCOVERY TODAY, 2016, 21 (10) : 1563 - 1565
- [29] Ethical Prioritization of Patients to CAR T-Cell Therapies: Tool Development and Process [J]. BLOOD, 2022, 140 : 2406 - 2407